-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prognosis in young patients with mantle cell lymphoma (MCL) has improved
Minimal residual lesion (MRD) analysis is a known prognostic prediction tool
Of the 300 patients enrolled, 250 (83%) all carried a molecular marker, allowing us to analyze
ASCT induced polymer remission (91% in peripheral blood and 83% in bone marrow).
To improve MRD performance, the researchers developed a time-changing model based on regularly updated MRD results and MIPI (International Prognostic Index for Mantle Cell Lymphoma), which showed an area of up to 0.
In summary, MRD is a strong predictor throughout the natural history of MCL, applicable to models
Original Source:
Simone Ferrero, Daniele Grimaldi, Elisa Genuardi, et al.